Organon’s VTAMA shows consistent efficacy across atopic dermatitis subgroups in pooled Phase 3 analysis
OGN•Organon will present a pooled post-hoc analysis of Phase 3 VTAMA cream trials at ACAAI on Nov. 14, 2026. The trials enrolled 813 adults and children aged 2 and older, and VTAMA improved disease severity and itch versus vehicle across evaluated subgroups.
1. Pooled trial analysis
The pooled post-hoc analysis covers Phase 3 trials enrolling 813 adults and children aged 2 and older with moderate to severe atopic dermatitis. VTAMA improved disease severity and itch versus vehicle across evaluated patient subgroups, with benefits appearing within one week and lasting through eight weeks.
2. Tolerability
The nonsteroidal topical treatment was well tolerated. Common adverse events included folliculitis, headache and respiratory infections.
